These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8448736)

  • 21. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
    Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
    Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
    Wadler S; Goldman M; Lyver A; Wiernik PH
    Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.
    Kemeny N; Younes A
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):171-5. PubMed ID: 1557642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.
    Piga A; Cascinu S; Latini L; Marcellini M; Bavosi M; Acito L; Bascioni R; Giustini L; Francini G; Pancotti A; Rossi G; Del Papa M; Carle F; Cellerino R
    Br J Cancer; 1996 Sep; 74(6):971-4. PubMed ID: 8826868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms.
    Pazdur R
    Br J Haematol; 1991 Oct; 79 Suppl 1():56-9. PubMed ID: 1931711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
    Pazdur R; Ajani JA; Patt YZ; Gomez J; Bready B; Levin B
    Cancer; 1993 Feb; 71(4):1214-8. PubMed ID: 8435795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
    Bazarbashi S; Abdelsalam M; Amin T; El-Bassiouni M; Soudy H; Elweshi A; Alhusseiny H; Rehman K; Memon M; Ajarim D
    Chemotherapy; 2008; 54(4):315-22. PubMed ID: 18701820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
    John WJ; Neefe JR; Macdonald JS; Cantrell J; Smith M
    Cancer; 1993 Dec; 72(11):3191-5. PubMed ID: 8242541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
    Knuth A; Bernhard H; Klein O; Meyer zum Büschenfelde KH
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):211-4. PubMed ID: 1557650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
    Pazdur R; Ajani JA; Patt YZ; Winn R; Jackson D; Shepard B; DuBrow R; Campos L; Quaraishi M; Faintuch J
    J Clin Oncol; 1990 Dec; 8(12):2027-31. PubMed ID: 2230894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study.
    Palmeri S; Gebbia V; Rausa L
    J Chemother; 1990 Oct; 2(5):327-30. PubMed ID: 2090772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction.
    Posner MC; Gooding WE; Landreneau RJ; Rosenstein MM; Clarke MR; Peterson MS; Lembersky BC
    Cancer J Sci Am; 1998; 4(4):237-46. PubMed ID: 9689982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.
    Slabber CF; Falkson G; Burger W; Schoeman L
    Invest New Drugs; 1996; 14(4):391-4. PubMed ID: 9157075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
    Pazdur R; Ajani JA; Winn R; Bearden J; Belt RJ; Pilat S; Hallinan R; Levin B
    Cancer; 1992 Feb; 69(4):878-82. PubMed ID: 1735078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.